These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 28007630)
41. Malignant mesothelioma with squamous differentiation. Tanaka H; Akiyama Y; Kitamura A; Matsumoto N; Tomita M; Kataoka H Histopathology; 2018 Jun; 72(7):1216-1220. PubMed ID: 29430704 [TBL] [Abstract][Full Text] [Related]
42. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report. Manur R; Lamzabi I Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731 [TBL] [Abstract][Full Text] [Related]
43. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555 [TBL] [Abstract][Full Text] [Related]
45. Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy. Pesatori AC; Mensi C Med Lav; 2005; 96(4):354-9. PubMed ID: 16457432 [TBL] [Abstract][Full Text] [Related]
47. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693 [TBL] [Abstract][Full Text] [Related]
48. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast. Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448 [TBL] [Abstract][Full Text] [Related]
49. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice. Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F; Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715 [TBL] [Abstract][Full Text] [Related]
51. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population. Gopar-Nieto R; Aguilar-Madrid G; Sotelo-Martínez L; Juárez-Pérez CA; Kelly-García J; Argote-Greene L; Ochoa-Vázquez MD; García-Bazán EM; Ramírez-Pérez J; Haro-García L; Jiménez-Ramírez C; Cabello-López A Arch Med Res; 2015 Feb; 46(2):107-11. PubMed ID: 25707292 [TBL] [Abstract][Full Text] [Related]
52. The established and future biomarkers of malignant pleural mesothelioma. Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846 [TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009 [TBL] [Abstract][Full Text] [Related]
55. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
56. Identifying malignant mesothelioma by a pathological survey using the São Paulo state hospital cancer registry, Brazil. Bernardi FDC; Algranti E; Dolhnikoff M; Pinto CAL; Oliveira IM; Coletta ENAM; Silva ECAD; Nunes AJF; Veneziano DB; Luizaga CTM; Lorenzi RL; Silva DRME; Mauad T J Bras Pneumol; 2024; 50(2):e20230343. PubMed ID: 38747814 [TBL] [Abstract][Full Text] [Related]
57. [Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia]. Barbieri PG; Lombardi S; Candela A; Pezzotti C; Binda I Med Lav; 2001; 92(4):249-62. PubMed ID: 11676187 [TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical panel for distinction between squamous cell carcinoma, adenocarcinoma and mesothelioma. Pritchard SA; Howat AJ; Edwards JM Histopathology; 2003 Aug; 43(2):197-9. PubMed ID: 12877739 [No Abstract] [Full Text] [Related]
59. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016). Barbieri PG Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233 [No Abstract] [Full Text] [Related]
60. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients]. Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]